Evidence map›Paper›PMID 39558550›Full record

ArticleNeuropathology and applied neurobiology2024

Microglia induce an interferon-stimulated gene expression profile in glioblastoma and increase glioblastoma resistance to temozolomide.

Mia Dahl Sørensen, Rikke Frydendahl Sick Olsen, Mark Burton, Stephanie Kavan, Stine Asferg Petterson, Mads Thomassen, Torben Arvid Kruse, Morten Meyer, Bjarne Winther Kristensen

Abstract read
In one paragraph

Article in Neuropathology and applied neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mia Dahl SørensenDepartment of Pathology, Odense University Hospital, Odense, Denmark.
Rikke Frydendahl Sick OlsenDepartment of Pathology, Odense University Hospital, Odense, Denmark.
Mark BurtonDepartment of Clinical Genetics, Odense University Hospital, Odense, Denmark.
Stephanie KavanDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark.
Stine Asferg PettersonDepartment of Pathology, Odense University Hospital, Odense, Denmark.
Mads ThomassenDepartment of Clinical Genetics, Odense University Hospital, Odense, Denmark.
Torben Arvid KruseDepartment of Clinical Genetics, Odense University Hospital, Odense, Denmark.
Morten MeyerDepartment of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Bjarne Winther KristensenDepartment of Pathology, Odense University Hospital, Odense, Denmark.

Funding

Brødrene Hartmann's FoundationKrista and Viggo Petersen FoundationNovo Nordisk Foundation NNF19OC0058427Oda and Hans Svenningsen's FoundationOdense University Hospital Research FundsThe Danish Cancer SocietyThe Danish Medical Research Council 4183-00183University of Southern Denmark
6 · The paper itself

Abstract

aimsGlioblastoma is the most malignant primary brain tumour. Even with standard treatment comprising surgery followed by radiation and concomitant temozolomide (TMZ) chemotherapy, glioblastoma remains incurable. Almost all patients with glioblastoma relapse owing to various intrinsic and extrinsic resistance mechanisms of the tumour cells. Glioblastomas are densely infiltrated with tumour-associated microglia and macrophages (TAMs). These immune cells affect the tumour cells in experimental studies and are associated with poor patient survival in clinical studies. The aim of the study was to investigate the impact of microglia on glioblastoma chemo-resistance.

methodsWe co-cultured patient-derived glioblastoma spheroids with microglia at different TMZ concentrations and analysed cell death. In addition, we used RNA sequencing to explore differentially expressed genes after co-culture. Immunostaining was used for validation.

resultsCo-culture experiments showed that microglia significantly increased TMZ resistance in glioblastoma cells. RNA sequencing revealed upregulation of a clear interferon-stimulated gene (ISG) expression signature in the glioblastoma cells after co-culture with microglia, including genes such as IFI6, IFI27, BST2, MX1 and STAT1. This ISG expression signature is linked to STAT1 signalling, which was confirmed by immunostaining. The ISG expression profile observed in glioblastoma cells with enhanced TMZ resistance corresponded to the interferon-related DNA damage resistance signature (IRDS) described in different solid cancers.

conclusionsHere, we show that the IRDS signature, linked to chemo-resistance in other cancers, can be induced in glioblastoma by microglia. ISG genes and the microglia inducing the ISG expression could be promising novel therapeutic targets in glioblastoma.

Indexed as

Antineoplastic Agents, AlkylatingDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticGlioblastomaInterferonsMicrogliaTemozolomideCell Line, TumorCell ProliferationCoculture TechniquesGene Expression ProfilingHumansSignal TransductionSTAT1 Transcription FactorAntineoplastic Agents, AlkylatingInterferonsSTAT1 protein, humanSTAT1 Transcription FactorTemozolomidechemo‐resistanceglioblastomainterferonmicrogliaSTAT

Identifiers

PMID39558550
PMCPMC11618491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.